Herriot Tabuteau, Chief Executive Officer at Axsome Therapeutics, Inc. (AXSM), sold 327,878 shares at $134.49 ($43.6M) on 2025-11-05, disclosed to the SEC on 2025-11-05.
Scheduled sale ($43.6M) by Chief Executive Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $132.34 | 91,705 | $12.1M | 27.8% |
| 2 | $132.34 | 91,705 | $12.1M | 27.8% |
| 3 | $133.79 | 50,459 | $6.8M | 15.5% |
| 4 | $133.79 | 50,459 | $6.8M | 15.5% |
| 5 | $134.49 | 21,775 | $2.9M | 6.7% |
| 6 | $134.49 | 21,775 |
| $2.9M |
| 6.7% |
| Total | $133.07 avg | 327,878 | $43.6M | 100% |
| Filing → |
| AXSM | SELL | 2026-06-09 | $12.0M | — | Filing → |
| AXSM | SELL | 2026-02-02 | $6.0M | — | Filing → |
| AXSM | SELL | 2026-01-07 | $23.9M | — | Filing → |